Drug intelligence / Profile preview

ZL-1

Development stage: Unknown
Lead developer: Shanghai Public Health Clinical Center
Modality: Small Molecules
Administration: Oral

Overview

ZL-1 is a drug currently undergoing clinical investigation for the treatment of HIV infection and Acquired Immunodeficiency Syndrome (AIDS). It is being developed by Shanghai Public Health Clinical Center and Beijing Century Health Medical & Pharmaceutical Development Co., Ltd. Clinical trials have explored ZL-1 as a standalone treatment and in combination with Highly Active Antiretroviral Therapy (HARRT). The Chinese names associated with ZL-1, 'Qudu Zengning Jiaonang' (Detoxification and Immunity-Boosting Capsule) and 'Qudu Zengning Moniji' (Detoxification and Immunity-Boosting Mimetic Agent), suggest its potential role as an immunomodulator or antiviral agent.

Other names: 袪毒增宁胶囊袪毒增宁模拟剂

Beyond the preview

Go deeper on ZL-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZL-1.

Explore the full profile